Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.

Literature DB >> 30407625

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.

Carlo Visco¹, Maria C Tisi¹, Andrea Evangelista², Alice Di Rocco³, Anna-Katharina Zoellner⁴, Vittorio R Zilioli⁵, Stefan Hohaus⁶, Roberta Sciarra⁷, Alessandro Re⁸, Cristina Tecchio⁹, Annalisa Chiappella¹⁰, Lucia Morello¹¹, Guido Gini¹², Luca Nassi¹³, Tommasina Perrone¹⁴, Anna L Molinari¹⁵, Alberto Fabbri¹⁶, Maria C Cox¹⁷, Erica Finolezzi¹⁸, Simone Ferrero¹⁹, Benedetta Puccini²⁰, Isabel Alvarez De Celis²¹, Annalisa Arcari²², Dario Marino²³, Michele Merli²⁴, Francesco Piazza²⁵, Massimo Gentile²⁶, Matteo Pelosini²⁷, Giacomo Loseto²⁸, Olivier Hermine²⁹, Martin Dreyling⁴, Marco Ruggeri¹, Maurizio Martelli³, Eva Hoster⁴, Umberto Vitolo¹⁰.

Abstract

Entities: Chemical Disease Species

Keywords: allogeneic transplant; cytarabine; mantle cell lymphoma; prognosis; refractory

Mesh：

Substances：

Year: 2018 PMID： 30407625 DOI： 10.1111/bjh.15643

Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

Review 1. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.

Authors: Meri Tarockoff; Teresita Gonzalez; Stanislav Ivanov; Jose Sandoval-Sus
Journal: Curr Oncol Rep Date: 2022-05-31 Impact factor: 5.945

2. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.

Authors: David A Bond; Jeffrey M Switchenko; Diego Villa; Kami Maddocks; Michael Churnetski; Alina S Gerrie; Subir Goyal; Krithika Shanmugasundaram; Oscar Calzada; Bhaskar Kolla; Veronika Bachanova; James N Gerson; Stefan K Barta; Brian T Hill; Yazeed Sawalha; Peter Martin; Edward Maldonado; Max Gordon; Alexey V Danilov; Natalie S Grover; Stephanie Mathews; Madelyn Burkart; Reem Karmali; Nilanjan Ghosh; Steven I Park; Narendranath Epperla; Talha Badar; Jin Guo; Mehdi Hamadani; Timothy S Fenske; Mary-Kate Malecek; Brad S Kahl; Christopher R Flowers; Kristie A Blum; Jonathon B Cohen
Journal: Blood Adv Date: 2021-12-14

Review 3. CAR T-Cell Therapy in the Older Person: Indications and Risks.

Authors: Geoffrey Shouse; Alexey V Danilov; Andy Artz
Journal: Curr Oncol Rep Date: 2022-04-14 Impact factor: 5.945

4. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.

Authors: Peter A Riedell; Mehdi Hamadani; Kwang W Ahn; Carlos Litovich; Claudio G Brunstein; Amanda F Cashen; Jonathon B Cohen; Narendranath Epperla; Brian T Hill; Annie Im; David J Inwards; John Lister; John M McCarty; Sai Ravi Kiran Pingali; Mazyar Shadman; Paul Shaughnessy; Melhem Solh; Patrick J Stiff; Julie M Vose; Mohamed A Kharfan-Dabaja; Alex F Herrera; Craig S Sauter; Sonali M Smith
Journal: Br J Haematol Date: 2021-09-28 Impact factor: 6.998

Review 5. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy.

Authors: Miriam Marangon; Carlo Visco; Anna Maria Barbui; Annalisa Chiappella; Alberto Fabbri; Simone Ferrero; Sara Galimberti; Stefano Luminari; Gerardo Musuraca; Alessandro Re; Vittorio Ruggero Zilioli; Marco Ladetto
Journal: Cancers (Basel) Date: 2021-01-14 Impact factor: 6.639

6. Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma.

Authors: Giulia Bega; Jacopo Olivieri; Marcello Riva; Greta Scapinello; Rossella Paolini; Silvia Finotto; Roberto Sartori; Elisa Lucchini; Gianmarco Guandalini; Davide Facchinelli; Maria Chiara Tisi; Marco Basso; Laura Ballotta; Francesco Piazza; Isacco Ferrarini; Carlo Visco
Journal: Cancers (Basel) Date: 2021-12-03 Impact factor: 6.639

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.

Review 1. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.

2. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.

Review 3. CAR T-Cell Therapy in the Older Person: Indications and Risks.

4. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.

Review 5. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy.

6. Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma.

7. Treatment Outcomes and Survival Patterns of Asian Patients With Relapsed/Refractory Mantle Cell Lymphoma.

8. Mantle cell lymphoma management trends and novel agents: where are we going?

Review 9. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.

10. Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience.